Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors

Abstract

Abstract:

ObjectiveTo analyze the tendency of elderly patients with breast cancer in the choice of treatment methods and related influencing factors.MethodsThe data of 312 elderly patients with unilateral breast cancer treated in Yuncheng Central Hospital from January 2013 to December 2017 were collected for retrospective analysis. All patients' treatment options were analyzed，and the age of patients who chose different treatment options was compared. Univariate and logistic regression were used to analyze the chemotherapy choice tendency of elderly breast cancer patients，and Cox proportional risk model was used to analyze the influencing factors of 5-year survival of elderly breast cancer patients.ResultsIn the whole patient population，the selection rates of surgery，chemotherapy，radiotherapy，endocrine therapy and targeted therapy were respectively 97.44% （304/312），81.41% （254/312），7.05% （22/312），68.27% （213/312），3.85% （32/312）. The mean age of all patients was （67.94±6.55） years. There were no statistically significant differences in the age of patients with different treatment methods （allP>0.05）. The results of univariate analysis showed that，there were statistically significant differences in the depth of invasive cancer （t=3.11，P=0.002），number of axillary lymph node metastasis （t=6.54，P<0.001），comorbidities （t=-4.85，P<0.001） and Eastern Cooperative Oncology Group （ECOG） score （t=-4.56，P<0.001） between chemotherapy and non-chemotherapy patients，and there were no statistically significant differences in age （t=-0.52，P=0.604），pathological type （χ²=4.96，P=0.084），surgical type （χ²=0.21，P=0.899），tumor differentiation degree （χ²=3.28，P=0.194），estrogen receptor （χ²=0.99，P=0.321），progesterone receptor （χ²=0.89，P=0.346），and human epidermal growth factor receptor-2 （χ²=0.58，P=0.445）. The results of multifactor analysis showed that types of comorbidities （OR=0.91，95%CI： 0.85-0.99，P=0.024） and ECOG score （OR=0.95，95%CI： 0.92-0.99，P=0.007） were independent influencing factors for the use of chemotherapy after surgery in elderly breast cancer patients. A total of 74 patients died within 5 years after surgery，and the 5-year overall survival rate was 76.28%. More axillary lymph node metastasis （RR=1.26，95%CI： 1.09-1.46，P=0.001） and more complications （RR=1.07，95%CI： 1.02-1.13，P=0.007） were risk factors for prognosis.ConclusionSurgery and chemotherapy are the main treatment methods for elderly patients with breast cancer. ECOG score and number of complications can directly affect the results of chemotherapy selection for such patients，the number of axillary lymph node metastasis and complications had significant influence on the long-term survival of the patients.

Key words:Old age,Breast neoplasms,Treatment mode,Chemotherapy,Radiotherapy,Complication

Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.

Figures/Tables4

项目	例（%）	年龄（ $\bar{x}$ ±s，岁）	t值	P值
手术
是	304（97.44）	67.21±5.54	-0.41	0.679
否	8（2.56）	68.03±5.12	-0.41	0.679
化疗
是	254（81.41）	67.72±5.08	-0.52	0.604
否	58（18.59）	68.12±6.13	-0.52	0.604
放疗
是	22（7.05）	66.99±5.48	-0.95	0.342
否	290（92.95）	68.23±5.92	-0.95	0.342
内分泌治疗
是	213（68.27）	68.10±6.13	0.62	0.538
否	99（31.73）	67.65±5.73	0.62	0.538
靶向治疗
是	32（3.85）	67.73±5.96	-0.45	0.653
否	280（96.15）	68.25±6.22	-0.45	0.653

项目	化疗（n=254）	未化疗（n=58）	t/χ²值	P值
年龄（岁）	67.72±5.08	68.12±6.13	-0.52	0.604
病理类型
浸润性导管癌	199（78.35）	38（65.52）
原位癌	17（6.69）	8（13.79）	4.96	0.084
其他类型	38（14.96）	12（20.69）
手术类型
保乳手术	58（22.83）	13（22.41）
改良根治术	189（74.41）	44（75.86）	0.21	0.899
其他	7（2.76）	1（1.72）
浸润癌深度（cm）	2.85±1.42	2.23±1.13	3.11	0.002
肿瘤分化程度
低分化	162（63.78）	32（55.17）
中分化	80（31.50）	20（34.48）	3.28	0.194
高分化	12（4.72）	6（10.34）
腋窝淋巴结转移数量（枚）	6.35±2.32	4.18±2.10	6.54	<0.001
雌激素受体
阴性	135（53.15）	35（60.34）	0.99	0.321
阳性	119（46.85）	23（39.66）	0.99	0.321
孕激素受体
阴性	140（55.12）	28（48.28）	0.89	0.346
阳性	114（44.88）	30（51.72）	0.89	0.346
人表皮生长因子受体-2
阴性	194（76.38）	47（81.03）	0.58	0.445
阳性	60（23.62）	11（18.97）	0.58	0.445
合并症（种）	2.12±1.08	2.86±0.89	-4.85	<0.001
ECOG评分（分）	1.73±0.51	2.08±0.60	-4.56	<0.001

影响因素	b值	S.E.值	Waldχ²值	OR值	95%CI	P值
浸润癌深度	0.10	0.06	2.71	1.11	0.98~1.25	0.099
腋窝淋巴结转移数量	0.23	0.15	2.54	1.26	0.95~1.67	0.111
合并症	-0.09	0.04	5.08	0.91	0.85~0.99	0.024
ECOG评分	-0.05	0.02	7.08	0.95	0.92~0.99	0.007

影响因素	单因素分析				多因素分析
影响因素	b值	RR值	95%CI	P值	b值	RR值	95%CI	P值
年龄	0.09	1.09	0.95~1.26	0.229
病理类型（浸润性导管癌为对照）
原位癌	1.25	3.50	0.60~20.31	0.162
其他类型	1.12	3.05	0.68~13.63	0.144
手术类型（保乳手术为对照）
改良根治术	2.35	10.53	0.85~130.40	0.066
其他	1.80	6.07	0.55~66.69	0.140
浸润癌深度	0.05	1.05	0.98~1.12	0.170
肿瘤分化程度（高分化为对照）
中分化	1.94	6.92	0.34~134.00	0.207
低分化	2.37	10.67	0.21~534.39	0.235
腋窝淋巴结转移数量	0.35	1.42	1.14~1.76	0.001	0.24	1.26	1.09~1.46	0.001
雌激素受体（阳性为对照）	1.36	3.88	0.66~22.85	0.133
孕激素受体（阳性为对照）	1.40	4.06	0.56~29.27	0.164
人表皮生长因子受体-2（阳性为对照）	1.29	3.63	0.42~31.59	0.242
合并症	0.05	1.05	1.03~1.07	0.001	0.07	1.07	1.02~1.13	0.007
ECOG评分	0.04	1.04	0.99~1.09	0.161

References21

[1]	Brand NR, Qu LG, Chao A, et al. Delays and barriers to cancer care in low- and middle-income countries: a systematic review[J].Oncologist,2019,24(12): e1371-e1380. DOI:10.1634/theoncologist.2019-0057.
[2]	Wu S, Li W, Zhang Q, et al. Comparison of complications between peripheral arm ports and central chest ports: a meta-analysis[J].J Adv Nurs,2018,74(11): 2484-2496. DOI:10.1111/jan.13766. pmid:29917252
[3]	Terra Branco M, de Araujo Brito Buttros D, Carvalho-Pessoa E, et al. Atherosclerotic disease and cardiovascular risk factors in postmenopausal breast cancer survivors: a case-control study[J].Climacteric,2019,22(2): 202-207. DOI:10.1080/13697137.2018.1551345. pmid:30624095
[4]	Zhang MM, Yang YJ, Su D, et al. A randomized controlled trial of a guided self-disclosure intervention to facilitate benefit finding in Chinese breast cancer patients: study protocol[J].J Adv Nurs,2019,75(8): 1805-1814. DOI:10.1111/jan.14042.
[5]	Yang X, Wu HX, Xiong C, et al. Comprehensive bioinformatics analysis of CYB561 expression in breast cancer: link between prognosis and immune infiltration[J].BIOCELL,2023,47(5): 1021-1037. DOI:10.32604/biocell.2023.027103.
[6]	Selvi A, Thilagamani S. Scale invariant feature transform with crow optimization for breast cancer detection[J].Intell Autom Soft Comput,2023,36(3): 2973-2987. DOI:10.32604/iasc.2022.029850.
[7]	林燕, 宋雨, 徐颖, 等. 简化老年综合评估分级在老年女性乳腺癌患者中的应用价值[J].中国医学科学院学报,2021,43(3): 395-401. DOI:10.3881/j.issn.1000-503X.13752.
[8]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5): 367-417. DOI:10.3969/j.issn.1007-3639.2011.05.010.
[9]	李君, 王兴华, 刘学改. 中老年乳腺癌化疗患者自我效能感与心理状态的关系及相关因素探讨[J].河南医学研究,2022,31(3): 478-481. DOI:10.3969/j.issn.1004-437X.2022.03.025.
[10]	Jaehoon S, Matthew FL, Iowis Z, et al. Antigen-dependent indu-cible T-cell reporter system for PET imaging of breast cancer and glioblastoma[J].J Nucl Med,2023,64(1): 137-144. DOI:10.2967/jnumed.122.264284.
[11]	苏闪闪, 郑蔚, 康婷婷, 等. 康复期老年乳腺癌患者疏离感现状及影响因素分析[J].解放军护理杂志,2021,38(8): 34-37. DOI:10.3969/ji.ssn.1008-9993.2021.08.010.
[12]	Pani N, Sahu P, Swain D, et al. Effects of fentanyl and dexmedetomidine as adjuvants to bupivacaine in paravertebral block for postoperative analgesia in patients undergoing modified radical mastectomy: aprospective randomised double-blind study[J].Indian J Anaesth,2022,66(Suppl 4): S193-S199. DOI:10.33545/26643766.2021.v4.i1c.268.
[13]	Mohamed SA, Abdel-Ghaffar HS, Hassan NA, et al. Pharmacokine-tics and pharmacodynamics of 3 doses of oral-mucosal dexmedetomidine gel for sedative premedication in women undergoing modified radical mastectomy for breast cancer[J].Anesth Analg,2021,132(2): 456-464. DOI:10.1213/ANE.0000000000005108.
[14]	Battisti NML, McCartney A, Biganzoli L. The conundrum of the association of chemotherapy with survival outcomes among elderly patients with curable luminal breast cancer[J].JAMA Oncol,2020,6(10): 1535-1537. DOI:10.1001/jamaoncol.2020.2194.
[15]	Overcash J, Ford N, Kress E, et al. Comprehensive geriatric assessment as a versatile tool to enhance the care of the older person diagnosed with cancer[J].Geriatrics (Basel),2019,4(2): 39. DOI:10.3390/geriatrics4020039.
[16]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[17]	Tamirisa N, Lin H, Shen Y, et al. Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer[J].JAMA Oncol,2020,6(10): 1548-1554. DOI:10.1001/jamaoncol.2020.2388.
[18]	Abedi A, Adelson J, Androudi S, et al. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258): 1250-1284. DOI:10.1016/S0140-6736(20)30750-9.
[19]	Savard MF, Clemons M, Hutton B, et al. De-escalating adjuvant therapies in older patients with lower risk estrogen receptorpositive breast cancer treated with breast-conserving surgery: a systematic review and meta-analysis[J].Cancer Treat Rev,2021,99: 102254. DOI:10.1016/j.ctrv.2021.102254.
[20]	Wan Q, Su L, Ouyang T, et al. Comparison of survival after breast conserving therapy vs mastectomy among patients with or without the BRCA1/2 variant in a large series of unselected Chinese patients with breast cancer[J].JAMA Netw Open,2021,4(4): e216259. DOI:10.3747/co.20.1543.
[21]	Mamtani A, Sevilimedu V, Le T, et al. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?[J].Cancer,2022,128(3): 471-478. DOI:10.1002/cncr.33929.